MORGAN v. QUEST DIAGNOSTIC INCORPORATED

CourtDistrict Court, D. New Jersey
DecidedSeptember 30, 2025
Docket2:20-cv-00430
StatusUnknown

This text of MORGAN v. QUEST DIAGNOSTIC INCORPORATED (MORGAN v. QUEST DIAGNOSTIC INCORPORATED) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MORGAN v. QUEST DIAGNOSTIC INCORPORATED, (D.N.J. 2025).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

DR. MICHAEL B. MORGAN, Case No. 2:20-CV-00430 (MEF) (SDA)

Plaintiff, OPINION

v. September 30, 2025

QUEST DIAGNOSTICS INCORPORATED,

Defendant.

STACEY D. ADAMS, United States Magistrate Judge

This matter is before the Court on the Motion of Plaintiff Dr. Michael B. Morgan (“Plaintiff”) seeking sanctions against Defendant Quest Diagnostics Incorporated (“Defendant”). (ECF No. 297). Defendant filed an opposition (ECF No. 301) and Plaintiff filed a reply (ECF No. 302).1 The motion was referred to the undersigned for resolution. (ECF No. 297). The Court heard oral argument on March 3, 2025.2 For the reasons set forth herein, Plaintiff’s Motion for Sanctions, and all relief requested therein, is DENIED. RELEVANT FACTUAL BACKGROUND AND PROCEDURAL HISTORY

In this action, Plaintiff alleges breach of contract and unjust enrichment stemming from the termination of his employment with Defendant on or about January 28, 2015. (Second Am. Compl., ECF Nos. 77 (redacted version), 78 (complete version filed under seal)). Plaintiff is a board-certified pathologist and dermatopathologist. (Id. ¶ 1). He started working at Dermpath

1 Defendant attempted to file a Sur-Reply (ECF No. 304-1), but the Court denied this request on January 13, 2025 and did not consider the filing. (ECF No. 306).

2 Following oral argument, Plaintiff attempted to submit a supplemental brief. (ECF No. 309). The Court denied this request and did not consider the filing. (ECF No. 312). Diagnostics in 1996, in its Tampa laboratory. (Id. ¶ 8). Quest acquired Dermpath in 2007. (Id. ¶ 10). In 2008, Plaintiff became the managing director of Defendant’s Tampa laboratory. (Id. ¶ 9). Plaintiff and Defendant subsequently entered into a five-year employment agreement covering the time period of November 1, 2012 through February 1, 2017. (Id., Exh. A). The Agreement

permitted Defendant to terminate Plaintiff’s employment for cause at any time upon written notice for 22 separate reasons. (Id., Exh. A, ¶ 14(a)). It also permitted Plaintiff to terminate his employment upon 120 days written notice. (Id., Exh. A, ¶ 14(b)). Finally, the Agreement provided that Defendant could terminate Plaintiff’s employment without cause at any time, which triggered a severance payment to Plaintiff. (Id., Exh. A, ¶ 14(c)). In January 2015, Defendant commenced an investigation over concerns that Plaintiff had fabricated the test results of patient, V.H. (PASMF, ECF No. 275).3 Specifically, Plaintiff issued a report on January 7, 2015 pertaining to a skin specimen taken from V.H. on December 11, 2014. (PASMF ¶ 85; Marquez Decl., Exh. 16). However, Quest had no record of receiving V.H.’s sample

3 Prior to the filing of the instant motion, Defendant filed a motion for summary judgment (ECF No. 261), which was fully briefed and then administratively terminated pending the outcome of this sanctions motion. (ECF No. 300). Because of the interrelationship between the two motions, both parties rely heavily on their respective statements of material fact and supporting declarations with exhibits in connection with this sanctions motion. Accordingly, the Court has reviewed these documents and will refer to them as follows: • Defendant’s 07/24/24 Statement of Undisputed Material Facts submitted in support of its motion for summary judgment (ECF No. 261-2) will be referred to as “DSUMF.” • The 07/24/24 Declaration of Ronald T. Coleman, Jr. Esq. submitted in support of Defendant’s motion for summary judgment (ECF No. 262) will be referred to as the “Coleman 07/24/24 Decl.” • Plaintiff’s 09/04/25 Additional Statements of Materially Disputed Facts (ECF No. 275) will be referred to as “PASMF.” • The 09/04/24 Declaration of Jorge Marquez submitted in opposition to the motion for summary judgment (ECF No. 274) will be referred to as the “Marquez Decl.” • The 10/07/24 Declaration of Ronald T. Coleman submitted in support of Defendant’s reply to the motion for summary judgment (ECF No. 289) will be referred to as the “Coleman 10/07/24 Decl.” from Dr. Michelle Foley of the Parks Dermatology Center (“Parks”). (PASMF ¶¶ 45-47; DSUMF ¶ 8). According to Plaintiff, Dr. Foley’s office had commingled patient samples in the past. (PASMF ¶ 370). Therefore, when the facility learned on December 30, 2014 that three samples

from Parks were missing, Plaintiff decided to check other samples taken by Dr. Foley on the same date. (PASMF ¶¶ 54, 62-70). Plaintiff claims that, on January 7, 2015, he discovered that V.H.’s sample had indeed been commingled with the sample from another Parks patient, G.D., which was designated with Accession No. BD-14. (PASMF ¶¶ 44, 66, 70-77). Plaintiff states he then instructed a laboratory supervisor, Caya Kalua-Markel, to separate the two tissue samples. (PASMF ¶ 78). He contends that Kalua-Markel removed V.H.’s tissue sample, placed it on a separate slide, and then brought it to Plaintiff to review. (ECF No. 298 at 5-6). Plaintiff claims he reviewed the new slide and issued a report and diagnosis for V.H. on January 7, 2015, which was assigned Accession No. BD-15. (PASMF ¶ 85; Marquez Decl., Exh. 16). Shortly thereafter, Defendant commenced a second investigation, concerned that Plaintiff

rendered his January 7, 2015 report for V.H. without a separate block and slide, from the sample of another patient, G.D. (PASMF ¶ 112). In connection with this investigation, Plaintiff claims that on January 13, 2015, Luis Soto, the Laboratory Operations Director, moved the tissue from BD-14 block and slide to another block and slide that he then designated with the same accession number previously assigned to V.H., BD-15. (PASMF ¶¶ 166-67). In doing so, Plaintiff argues, Soto destroyed the original BD-15 block and slide created by Kalua-Markel on January 7, 2015. (PASMF ¶ 187). This, Plaintiff claims, constitutes impermissible spoliation of evidence warranting sanctions. (ECF No. 298 at 4). Defendant has a different version of events. According to Defendant, Plaintiff opened a case for V.H., assigned it Accession No. BD-15, and then rendered a report for V.H. based upon the BD-14 slide. (DSUMF ¶ 10; Marquez Decl., Exh. 13 at 111). Soto became concerned that Plaintiff had opened an accession number and issued a pathology report for V.H. based only on a

single slide that was already accessioned to a different patient case, BD-14. (Coleman 07/24/24 Decl., Exh. O). When Soto showed the BD-14 slide to other dermatopathologists, they did not see two different tissue samples. (Id.). Soto elevated his concerns and there was a telephone conference on January 13, 2015 with Plaintiff, Soto, Damon Ball (Soto’s supervisor) and Dr. Edward Kramer (VP of Dermatopathology). (Coleman 07/24/24 Decl., Exh. A at 212; Exh. O at 271-73).4 Based upon Plaintiff’s claim that he had discovered a second tissue specimen belonging to V.H. on BD- 14, Plaintiff and others at the meeting directed the alleged two specimens on the BD-14 slide to be separated so that a separate and unique block and slide could be assigned to the V.H. specimen and associated with the new BD-15 case that Plaintiff had opened at the time he prepared the January 7, 2015 report. (Coleman 07/24/24 Decl., Exh. O at 271-73). The new slide and block

were created on January 13, 2025 and assigned Accession No. BD-15. (Id. at 270-74). Soto did not personally create the BD-15 block and slide; they were done by someone qualified to do so in the laboratory. (Baroody Decl. (ECF No. 301-1), Exh. 3, ¶ 7). The Florida Department of Health thereafter commenced an investigation into the incident. Plaintiff’s counsel submitted a response to the Administrative Complaint on Plaintiff’s behalf on July 25, 2015, which was signed by Plaintiff. (Coleman 10/07/24 Decl., Exh. R at 11).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Chambers v. Nasco, Inc.
501 U.S. 32 (Supreme Court, 1991)
Bull v. United Parcel Service, Inc.
665 F.3d 68 (Third Circuit, 2012)
Stephen Omogbehin v. Secretary Transp
485 F. App'x 606 (Third Circuit, 2012)
Mosaid Technologies Inc. v. Samsung Electronics Co.
348 F. Supp. 2d 332 (D. New Jersey, 2004)
Anita Peterson v. Attorney General Pennsylvania
551 F. App'x 626 (Third Circuit, 2014)
Dilworth v. Goldberg
3 F. Supp. 3d 198 (S.D. New York, 2014)
Scott v. IBM Corp.
196 F.R.D. 233 (D. New Jersey, 2000)
Kunlgunda Dirauf v. Lawrence Berger
57 F.4th 101 (Third Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
MORGAN v. QUEST DIAGNOSTIC INCORPORATED, Counsel Stack Legal Research, https://law.counselstack.com/opinion/morgan-v-quest-diagnostic-incorporated-njd-2025.